Ultimovacs Q4 2023: One month to judgement day - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Ultimovacs Q4 2023: One month to judgement day - Redeye

{newsItem.title}

Redeye comments on Ultimovacs’ Q4 2023 report, with the company having confirmed its intention to communicate INITIUM top-line data in March 2024e. These top-line data have been a long time coming and will represent a proverbial ‘fork in the road’ for Ultimovacs.

Länk till analysen i sin helhet: https://www.redeye.se/research/979098/ultimovacs-q4-2023-one-month-to-judgement-day?utm_source=finwire&utm_medium=RSS

Nyheter om Ultimovacs

Läses av andra just nu

Om aktien Ultimovacs

Senaste nytt